Stock Report: BioDelivery Sciences International Inc. (BDSI) Report Updated: May 20, 2013 | Print This Page

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, focuses on developing and commercializing therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its pain franchise consists of products utilizing the patented BEMA technology, including ONSOLIS, a fentanyl buccal soluble film for the management of pain in opioid tolerant adult patients with cancer; and BEMA Buprenorphine that has completed a Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population, as well as BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence. The company also develops BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop, manufacture, market, and sell BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.